ABOS
insider transactionsAcumen Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-38.7K
0 buy · 38.7K sell
Net value · 30d
-$89.5K
$0 in · $89.5K out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
4
0 buy · 38.7K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Director
$0
13.0K sh
Own New
-
Sell·S
Director
$30.3K
13.0K sh · $2.33
Own -27%
-
Exercise·M
Director
$14.0K
13.0K sh · $1.07
Own +37%
-
Sell·S
Director
$29.8K
12.8K sh · $2.33
Own -27%
-
Exercise·M
Director
$0
6.5K sh
Own +98%
-
Sell·S
Director
$15.1K
6.5K sh · $2.35
Own -12%
-
Exercise·M
Director
$6.9K
6.5K sh · $1.07
Own +13%
-
Sell·S
Director
$14.3K
6.4K sh · $2.23
Own -12%
-
Grant·A
Director
$0
53.2K sh
Own New
-
Grant·A
Director
$0
35.5K sh
Own +186%
-
Grant·A
Director
$0
53.2K sh
Own New
-
Grant·A
Director
$0
35.5K sh
Own +277%
-
Grant·A
Director
$0
53.2K sh
Own New
-
Grant·A
Director
$0
35.5K sh
Own +19%
-
Grant·A
Director
$0
53.2K sh
Own New
-
Grant·A
Director
$0
35.5K sh
Own +277%
-
Grant·A
Director
$0
53.2K sh
Own New
-
Grant·A
Director
$0
35.5K sh
Own +277%
-
Grant·A
Director
$0
53.2K sh
Own New
-
Grant·A
Director
$0
35.5K sh
Own New
-
Grant·A
Director
$0
53.2K sh
Own New
-
Grant·A
Director
$0
35.5K sh
Own +277%
-
Grant·A
Director, 10% Owner
$0
53.2K sh
Own New
-
Grant·A
Director, 10% Owner
$0
35.5K sh
Own +277%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Derrell Porter | Exercise M | 13.0K | $0 |
| Jun 17, 2026 | Derrell Porter | Sell S | 13.0K | $30.3K |
| Jun 17, 2026 | Derrell Porter | Exercise M | 13.0K | $14.0K |
| Jun 16, 2026 | Derrell Porter | Sell S | 12.8K | $29.8K |
| Jun 15, 2026 | Derrell Porter | Exercise M | 6.5K | $0 |
| Jun 15, 2026 | Derrell Porter | Sell S | 6.5K | $15.1K |
| Jun 15, 2026 | Derrell Porter | Exercise M | 6.5K | $6.9K |
| Jun 9, 2026 | Nathan B Fountain | Sell S | 6.4K | $14.3K |
| Jun 3, 2026 | Nathan B Fountain | Grant A | 53.2K | $0 |
| Jun 3, 2026 | Nathan B Fountain | Grant A | 35.5K | $0 |
| Jun 3, 2026 | Kimberlee C Drapkin | Grant A | 53.2K | $0 |
| Jun 3, 2026 | Kimberlee C Drapkin | Grant A | 35.5K | $0 |
| Jun 3, 2026 | John A Stalfort III | Grant A | 53.2K | $0 |
| Jun 3, 2026 | John A Stalfort III | Grant A | 35.5K | $0 |
| Jun 3, 2026 | Derrell Porter | Grant A | 53.2K | $0 |
| Jun 3, 2026 | Derrell Porter | Grant A | 35.5K | $0 |
| Jun 3, 2026 | Jeffrey L. Ives | Grant A | 53.2K | $0 |
| Jun 3, 2026 | Jeffrey L. Ives | Grant A | 35.5K | $0 |
| Jun 3, 2026 | George Golumbeski | Grant A | 53.2K | $0 |
| Jun 3, 2026 | George Golumbeski | Grant A | 35.5K | $0 |
| Jun 3, 2026 | Laura Stoppel | Grant A | 53.2K | $0 |
| Jun 3, 2026 | Laura Stoppel | Grant A | 35.5K | $0 |
| Jun 3, 2026 | RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund II, L.P. / Peter Kolchinsky / Rajeev M. Shah | Grant A | 53.2K | $0 |
| Jun 3, 2026 | RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund II, L.P. / Peter Kolchinsky / Rajeev M. Shah | Grant A | 35.5K | $0 |
About ABOS insider trading
This page tracks insider transactions for Acumen Pharmaceuticals, Inc. (ABOS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.